Www.innovotech.ca © Innovotech, 2009 Annual General Meeting 20 April 2010 Edmonton, Alberta...

www.innovotech.ca © Innovotech, 2009

Annual General Meeting Annual General Meeting

20 April 201020 April 2010Edmonton, AlbertaEdmonton, Alberta

Innovotech Inc.Innovotech Inc.


A G E N D AA G E N D A WelcomeWelcome Formal Administrative BusinessFormal Administrative Business Adjournment of AGMAdjournment of AGM Business UpdateBusiness Update Q&AQ&A



Formal Administrative BusinessFormal Administrative Business



Election of Directors:Election of Directors: Dr Lorne BabiukDr Lorne Babiuk Mr Kerry Brown Mr Kerry Brown Mr Bruce D. Hirsche Q.C.Mr Bruce D. Hirsche Q.C. Dr Wolfgang H. MuhsDr Wolfgang H. Muhs Mr John PinsentMr John Pinsent Dr Gerard TertzakianDr Gerard Tertzakian Dr James TimourianDr James Timourian


Innovotech Business UpdateInnovotech Business Update


2009 – Moving to Market2009 – Moving to Market

Objectives & Performance in 2009Objectives & Performance in 2009


2009 Financial Results 2009 Financial Results

20092009 20082008

RevenueRevenue $1,453,924$1,453,924 $1,164,035$1,164,035

Gross MarginGross Margin $813,629$813,629 $695,409$695,409

Overhead CostsOverhead Costs $984,178$984,178 $909,588$909,588

R&D ExpendituresR&D Expenditures $809,326$809,326 $708,007$708,007

EBITEBIT ($1,136,783)($1,136,783) ($983,261)($983,261)

Accumulated DeficitAccumulated Deficit ($3,618,938)($3,618,938) ($2,491,735)($2,491,735)

Shares Outstanding Shares Outstanding (wa)(wa) 23,985,78423,985,784 21,907,35221,907,352

Cash Reserves (Dec 31)Cash Reserves (Dec 31) $1,375,559$1,375,559 $2,120,859$2,120,859


bioFILM PA - ObjectivesbioFILM PA - Objectives

bioFILM PA goals for 2009:bioFILM PA goals for 2009: RevenueRevenue Expand through commercial partnerExpand through commercial partner

Path:Path: Canada: Maintain current planCanada: Maintain current plan USA: “Research Use Only” through PartnerUSA: “Research Use Only” through Partner Convert to dry panelConvert to dry panel


bioFILM PA -Stakeholders bioFILM PA -Stakeholders

LaboratoryUser

DoctorsDecision-maker

Alberta HealthPayer

IOT

PatientsRecipient


bioFILM - Market potentialbioFILM - Market potential

Market - bioFILM PA:Market - bioFILM PA: CanadaCanada USUS WorldWorld Cystic FibrosisCystic Fibrosis $2.4M$2.4M $24M$24M $50M$50M Ventilator Associated PneumoniaVentilator Associated Pneumonia $35M$35M $70M$70M Other (burns, wounds)Other (burns, wounds) tbdtbd

Market – bioFILM SA:Market – bioFILM SA: CanadaCanada USUS WorldWorld CathetersCatheters DialysisDialysis Other (CF, VAP)Other (CF, VAP)

TotalTotal>$150M>$150M


bioFILM PA – 2010 ObjectivesbioFILM PA – 2010 Objectives

Revenue in CanadaRevenue in Canada Published paper Published paper Health economic evaluationHealth economic evaluation

Enter other marketsEnter other markets US through private diagnostic laboratoryUS through private diagnostic laboratory IsraelIsrael

SA developmentSA development Low cost and quick developmentLow cost and quick development Augments PA disease use (CF and VAP)Augments PA disease use (CF and VAP)


Agress – ObjectivesAgress – Objectives

Agress Agress goals for 2009:goals for 2009: Regulatory approval for pulsesRegulatory approval for pulses Commercial agreementCommercial agreement

Path:Path: Maintain current Co interestMaintain current Co interest Potential reg filing for Fire BlightPotential reg filing for Fire Blight Develop AUS R&DDevelop AUS R&D Launch in N America for pulses post-09Launch in N America for pulses post-09


Agress – PMRA (Canada) Agress – PMRA (Canada)

CurrentCurrent situation: situation: Innovotech denied waiver Innovotech denied waiver

claimsclaims Asked to re-submit with Asked to re-submit with

expedited review for expedited review for approved componentsapproved components

Fees partially refundedFees partially refunded 4 crops, 13 diseases, 1 use 4 crops, 13 diseases, 1 use

patternpattern

New submission:New submission: Determine EPA stanceDetermine EPA stance Use Syngenta regulatory Use Syngenta regulatory

teamteam Evaluate current consultantsEvaluate current consultants 8 crops, 25 diseases, 2 use 8 crops, 25 diseases, 2 use

patternspatterns


Agress – Syngenta partnershipAgress – Syngenta partnership

Agress to be used as “anti-bacterial” component of many Agress to be used as “anti-bacterial” component of many productsproducts

Syngenta press release on partnershipSyngenta press release on partnership Post-trade show orders of 1.5kg of AgressPost-trade show orders of 1.5kg of Agress Syngenta (US) interest in Pithium data in cornSyngenta (US) interest in Pithium data in corn


Agress – 2010 ObjectivesAgress – 2010 Objectives

Expand product claimsExpand product claims Crop, Disease and Use patternCrop, Disease and Use pattern Incorporate Syngenta trialsIncorporate Syngenta trials

Remove regulatory hurdlesRemove regulatory hurdles Meet with agenciesMeet with agencies Draw on external scientific expertiseDraw on external scientific expertise

Maintain flexibility with other companiesMaintain flexibility with other companies


Silver Periodate opportunitySilver Periodate opportunity

Unique propertiesUnique properties Patentable discoveryPatentable discovery Interest of medical device and agriculture companiesInterest of medical device and agriculture companies Assembly of internal teamAssembly of internal team


2010 – Objectives2010 – Objectives

Our goals for 2010:Our goals for 2010: bioFILM PA™bioFILM PA™

Agress Agress

R&DR&D

Contract ResearchContract Research

RevenueRevenue Enter US marketEnter US market Expand claimsExpand claims Remove regulatory hurdlesRemove regulatory hurdles Product candidate from Silver periodateProduct candidate from Silver periodate Develop bioFILM SADevelop bioFILM SA Photo-dynamic approval as sanitizerPhoto-dynamic approval as sanitizer Revenue growthRevenue growth


Contact InformationContact Information

Ken Boutilier, President Ken Boutilier, President Innovotech Inc.Innovotech [email protected] Ph: 780-448-0585 ext 221Ph: 780-448-0585 ext 221Fax: 780-424-0941Fax: 780-424-0941


2008 Summary - Agress™2008 Summary - Agress™

Seed Treatment, Pulse cropsNorth America$3-5M

Seed Treatment, All cropsNorth America$120M

Seed & FoliarAll crops

World$20B+

Factors: Treatment is based on disease pressure Crop guarantees by sellers increases treatments A suitable antibacterial is lacking Formulations are as important as “actives” Agress will be in a combination with other agents


Agress – Market Potential Agress – Market Potential

Markets

Agress is price competitive in all markets!

Www.innovotech.ca © Innovotech, 2009 Annual General Meeting 20 April 2010 Edmonton, Alberta...

Documents

Transcript of Www.innovotech.ca © Innovotech, 2009 Annual General Meeting 20 April 2010 Edmonton, Alberta...